Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
05 Giugno 2024 - 1:00PM
Business Wire
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company
interrogating extrachromosomal DNA (ecDNA) biology to deliver
transformative therapies to patients with previously intractable
oncogene amplified cancers, today announced that Zachary Hornby,
President and Chief Executive Officer, and Jami Rubin, Chief
Financial Officer, will participate in a fireside chat at the
Goldman Sachs 45th Annual Global Healthcare Conference.
The fireside chat session is scheduled for Wednesday, June 12,
in Miami, FL, at 3:20 p.m. ET. A live and archived webcast of the
session will be accessible under “Events & Presentations” in
the Investors section of Boundless Bio’s website.
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to
unlocking a new paradigm in cancer therapeutics to address the
significant unmet need of patients with oncogene amplified tumors
by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene
amplification observed in more than 14% of cancer patients.
Boundless Bio is developing the first ecDNA-directed therapy
(ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1
(CHK1) being evaluated in a Phase 1/2 clinical trial in patients
with oncogene amplified cancers. Boundless Bio’s second ecDTx,
BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR)
being evaluated in a Phase 1/2 clinical trial in cancer patients
with resistance gene amplifications. Leveraging its Spyglass
platform, Boundless Bio has additional programs advancing through
preclinical development and discovery. Boundless Bio is
headquartered in San Diego, CA.
For more information, visit www.boundlessbio.com.
Follow us on LinkedIn and X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240603162858/en/
Ben Flaum, Boundless Bio bflaum@boundlessbio.com
Investors THRUST Strategic Communications Renee Leck
renee@thrustsc.com
Media 1AB Dan Budwick dan@1abmedia.com
Grafico Azioni Boundless Bio (NASDAQ:BOLD)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Boundless Bio (NASDAQ:BOLD)
Storico
Da Giu 2023 a Giu 2024
